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In the present study, we show that in human endothelial cells the tetraspanin CD63/lamp3
distributes predominantly to the internal membranes of multivesicular–multilamellar late endo-
somes, which contain the unique lipid lysobisphosphatidic acid. Some CD63/lamp3 is also
present in Weibel–Palade bodies, the characteristic secretory organelle of these cells. We find that
CD63/lamp3 molecules can be transported from late endosomes to Weibel–Palade bodies and
thus that CD63/lamp3 cycles between endocytic and biosynthetic compartments; however, move-
ment of CD63/lamp3 is much slower than that of P-selectin, which is known to cycle between
plasma membrane and Weibel–Palade bodies. When cells are treated with U18666A, a drug that
mimics the Niemann-Pick type C syndrome, both proteins accumulate in late endosomes and fail
to reach Weibel–Palade bodies efficiently, suggesting that P-selectin, like CD63/lamp3, cycles via
late endosomes. Our data suggest that CD63/lamp3 partitions preferentially within late endo-
some internal membranes, thus causing its accumulation, and that this mechanism contributes to
CD63/lamp3 retention in late endosomes; however, our data also indicate that the protein can
eventually escape from these internal membranes and recycle toward Weibel–Palade bodies to be
reused. Our observations thus uncover the existence of a selective trafficking route from late
endosomes to Weibel–Palade bodies.
INTRODUCTION
Vascular endothelial cells, which play an essential role in
blood coagulation and inflammatory processes, are charac-
terized by the presence of specialized rod-shaped secretory
granules called Weibel–Palade bodies (Weibel and Palade,
1964). Weibel–Palade bodies store and secrete von Wille-
brand factor (vWF), an adhesive glycoprotein involved in
primary hemostasis (Wagner et al., 1982; Wagner, 1990).
These storage granules also contain P-selectin, a membrane
protein involved in leukocyte adhesion to the plasma mem-
brane of the endothelium (Wagner, 1993). Although few
other membrane proteins of the Weibel–Palade bodies have
been identified until now, Vischer and Wagner (1993)
showed that these storage granules contain CD63.
CD63 is a well-established component of the late endoso-
mal and lysosomal membranes, also known as lysosome-
associated membrane protein 3 (lamp3) or lysosome integral
membrane protein 1 (limp1) (Fukuda, 1991; Escola et al.,
1998; Kobayashi et al., 1999), which will be referred to here as
CD63/lamp3. Unlike lamp1 or lamp2, which are typical
type-1 transmembrane proteins, CD63/lamp3 is a member
of the tetraspanin superfamily (Metzelaar et al., 1991; Mae-
cker et al., 1997). CD63/lamp3, however, appears to share
with lamp1 and lamp2 a cytoplasmic Gly-Tyr motif, which
has been reported to serve as a lysosomal targeting signal
(Hunziker and Geuze, 1996). In addition, CD63/lamp3 is
also present in “secretory lysosomes” (Griffiths, 1996), the
secretory granules of cells derived from the hemopoietic
lineage that are related to lysosomes. These organelles in-
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clude azurophilic granules of neutrophils (Cieutat et al.,
1998) and a-granules of platelets (Heijnen et al., 1998). Inter-
estingly, the expression of vWF is tissue specific and re-
stricted to Weibel–Palade bodies of endothelial cells and
a-granules of megakaryocytes and platelets (Wagner, 1993).
Thus, CD63/lamp3 appears to be shared by conventional
late endosomes/lysosomes and by specialized, perhaps re-
lated secretory organelles.
In the present study, we report that in human umbilical
vein endothelial cells (HUVEC), the vast majority of CD63/
lamp3 is present within the complex network of internal
membranes characteristic for late endosomes in animal cells.
CD63/lamp3 is also present in Weibel–Palade bodies, as
expected from previous studies. We made use of the fact that
CD63/lamp3 can be labeled with endocytosed antibodies to
follow the fate of the protein. Our data show that CD63/
lamp3 is transported from late endosomes to Weibel–Palade
bodies and thus uncover the existence of a trafficking route
from late endosomes to this secretory organelle. P-selectin
appears to follow the same route, albeit with faster kinetics.
Thus, CD63/lamp3, like P-selectin, can cycle between endo-
cytic and exocytic compartments in endothelial cells. Our
data also suggest that the CD63/lamp3 residence time in late
endosome is relatively long because the protein accumulates
within late endosome internal membranes, but that the pro-
tein can eventually recycle from these internal membranes to
be reused.
MATERIALS AND METHODS
Cells and Reagents
HUVEC were isolated and maintained as described (Vischer and
Wollheim, 1998). The monoclonal antibodies against CD63/lamp3
(2C6) (Vischer and Wagner, 1993) and lysobisphosphatidic acid
(LBPA) (6C4) (Kobayashi et al., 1998) have been described. Mono-
clonal anti-CD63/lamp3 antibody was also purchased from Chemi-
con (Temecula, CA). The monoclonal antibody against human P-
selectin was from H.K. Nieuwenhuis (University Hospital Utrecht,
The Netherlands). The monoclonal antibody against the human
lysosomal-associated membrane protein 2 (lgp 110/lamp2) (H4B4)
(Chen et al., 1985) was from the Developmental Studies Hybridoma
Bank (Iowa City, IA). Antibodies against giantin (Linstedt and
Hauri, 1993) were kindly provided by Hans-Peter Hauri (University
of Basel, Basel, Switzerland). Rabbit antibodies against human vWF
were from Dako (Glostrup, Denmark). Aminomethylcoumarin ace-
tate (AMCA)-conjugated donkey F(ab9)2 against rabbit antibodies,
FITC-conjugated goat anti-mouse antibodies, and rhodamin-conju-
gated goat anti-rabbit antibodies were from Jackson (West Grove,
PA). Oregon Green-labeled antibodies and Alexa 568-labeled anti-
bodies were prepared according to the manufacturer’s instruction
(Molecular Probes, Eugene, OR). 3b-(2-Diethylaminoethoxy)-andro-
stenone.HCl (U18666A) was from Biomol (Plymouth Meeting, PA).
In Vivo Labeling of Endothelial Cells
HUVEC were grown on gelatin-coated coverslips in RPMI 1640
containing 90 mg/ml heparin (Boehringer Ingelheim, Heidelberg,
Germany), 15 mg/ml endothelial cell growth supplement (Upstate
Biotechnology, Lake Placid, NY), 10 mM HEPES, 100 U/ml penicil-
lin, and 100 U/ml streptomycin, and supplemented with 10% FCS.
mAbs against CD63/lamp3 or mAbs against P-selectin were added
to the culture medium, when indicated. At the desired time, cells
were washed, fixed, and permeabilized for fluorescence microscopy
as described below. Internalized antibodies were either visualized
by indirect immunofluorescence using secondary antibodies or after
coupling the fluorophore directly to the purified, primary antibody.
The intracellular distribution of fluorescent and nonfluorescent an-
tibodies was identical, and no difference was observed when either
detection system was used.
Fluorescence Microscopy
HUVEC grown on coverslips were fixed with 4% freshly depoly-
merized paraformaldehyde in PBS at pH 7.4 (room temperature for
20 min). Cells were washed with PBS, treated for 10 min with 0.27%
NH4Cl/0.38% glycine in PBS, and permeabilized for 30 min with
0.05% saponin in PBS in the presence of primary antibodies. Cells
were washed and then incubated for 30 min with fluorescent sec-
ondary antibodies. After washing, coverslips were mounted in poly-
vinyl alcohol and examined under a Zeiss Axiophot microscope.
Rhodamin, Alexa 568, Oregon green, FITC, and AMCA signal were
recorded sequentially using a 633 Plan-NEOFLUAR oil immersion
objective. Filipin staining of cholesterol was performed as described
(Kobayashi et al., 1999).
Electron Microscopy
HUVEC were prepared for electron microscopy and cryo-sectioned,
and then sections were processed for immunogold labeling as de-
scribed (Griffiths et al., 1984).
RESULTS
CD63/lamp3 Is Present in Both Late Endosomes and
Weibel–Palade Bodies in HUVEC
We analyzed the distribution of CD63/lamp3 in HUVEC by
immunofluorescence. As expected (Vischer and Wagner,
1993), we found that the protein was present in Weibel–
Palade bodies (Figure 1), identified by their characteristic,
rod-shaped appearance, and the presence of vWF, the main
cargo protein of Weibel–Palade bodies (Wagner, 1990); how-
ever, the vast majority of the protein distributed to intracel-
lular structures with a labeling pattern resembling that of
endosomes/lysosomes (Figure 1).
We have previously described a late endosome-specific
mAb (6C4) that recognizes the poorly degradable phos-
pholipid LBPA (Kobayashi et al., 1998). We found that this
lipid is restricted to the complex membrane network that
accumulates within multivesicular–multilamellar late en-
dosomes, in all cell types we have tested (Kobayashi et al.,
1998; Kobayashi et al., 1999; Schaible et al., 1999). As
shown in Figure 1, the numerous structures that contain
CD63/lamp3 but are devoid of vWF labeling were effi-
ciently double-labeled with the anti-LBPA mAb. CD63
was not detected in the Golgi complex (Figure 1), which
was labeled with antibodies against giantin (Linstedt and
Hauri, 1993). These observations demonstrate that some
CD63/lamp3 distributes to Weibel–Palade bodies in
HUVEC but that the bulk of the protein is present in late
endosomes, in agreement with previous observations
(Vischer and Wagner, 1993).
CD63/lamp3 Distributes to Late Endosome Internal
Membranes in HUVEC
We then investigated the ultrastructure of membranes con-
taining CD63/lamp3 by immunogold labeling of cryosec-
tions. As shown in Figure 2, Weibel–Palade bodies, which
could be unambiguously identified on cryosections because
of their characteristic rod-shaped appearance, were signifi-
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cantly labeled by anti-CD63/lamp3 antibodies. Previously,
it was estimated that Weibel–Palade bodies contain ’5% of
the total cellular content of CD63/lamp3 (Vischer and Wag-
ner, 1993). This value is in good agreement with the distri-
bution of gold particles on cryosections. As observed previ-
ously (Vischer and Wagner, 1993), CD63/lamp3 was not
detected on the plasma membrane by immunofluorescence
or immunogold labeling.
Anti-CD63/lamp3 antibodies labeled structures with the
typical multivesicular appearance of late endosomes, in
agreement with our immunofluorescence study; however,
gold particles exhibited a characteristic distribution: they
were mostly observed on the internal membranes of late
endosomes (Figure 2), as in other cell types (Escola et al.,
1998; Hammond et al., 1998). This distribution is in marked
contrast to that of lgp120/lamp1, which is restricted to the
Figure 1. Steady-state distribution of CD63/lamp3 in HUVEC. (A) HUVEC were fixed and triple-labeled with Alexa 568-conjugated
monoclonal anti-LBPA antibodies, Oregon Green-conjugated monoclonal anti-CD63/lamp3 antibodies, and rabbit anti-vWF antibodies
followed by AMCA-conjugated donkey F(ab9)2 against rabbit antibodies. Arrowheads show LBPA-positive late endosomes, whereas arrows
show vWF-positive Weibel–Palade bodies. Bar, 10 mm. (B) HUVEC were double-labeled with Alexa 568-conjugated monoclonal antibody
against CD63/lamp3 (arrowheads) and rabbit anti-giantin antibodies (arrows) followed by FITC-conjugated donkey F(ab)2 against rabbit
antibodies. CD63/lamp3 can be detected in structures with the typical appearance of late endosomes or Weibel–Palade bodies but not in the
Golgi complex. Bar, 10 mm.
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Figure 2. Ultrastructure of compartments containing CD63/lamp3 in HUVEC. Ultrathin frozen sections of HUVEC were labeled with
CD63/lamp3 antibodies followed by 10 nm goat anti-mouse gold. (A) Low-power overview showing the general distribution of CD63/lamp3
labeling. Multivesicular late endosomes (arrowheads) show labeling on intralumenal vesicles (arrows). The ER surrounding the nucleus (N)
as well as the Golgi complex (G) is not labeled. A representative image of a putative late endosome in which intralumenal vesicles are labeled
(arrows) is shown in E. B–D show examples of Weibel–Palade bodies that show significant, albeit low, labeling for CD63/lamp3 (arrows).
Bars, 100 nm.
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limiting membranes of the same organelle (Griffiths et al.,
1988; Aniento et al., 1993; Kobayashi et al., 1998). In fact, a
quantitative analysis of CD63/lamp3 distribution revealed
that 88% of the gold particles present in late endosomes
distributed to internal membranes. We recently showed that
in HUVEC as in other cells, LBPA distributes to late endo-
some internal membranes (Galve de Rochemonteix et al.,
2000). Our observations thus strongly suggest that CD63/
lamp3 partitions preferentially within LBPA-rich membrane
domains in the late endosomes of HUVEC.
Internalized Anti-CD63/lamp3 Antibodies Are
Transported to Late Endosomes and Weibel–Palade
Bodies
We then made use of the fact that the endosomal pool of
CD63/lamp3 is accessible to antibodies internalized from
the medium to study the fate of the protein. Because CD63/
lamp3 was not detected on the plasma membrane, antibod-
ies were presumably internalized, at least in part, by fluid-
phase endocytosis. It is also possible that internalization was
facilitated by the presence of low, below detection amounts
of the protein cycling at the cell surface. Cells were first
incubated for 24 h in the presence of antibodies to label
efficiently the intracellular pools of CD63/lamp3, which
may intersect with the endocytic pathway. As shown in
Figure 3, the internalized antibody accumulated intracellu-
larly, predominantly in late endosomes; however, anti-
CD63/lamp3 antibodies were also detected within Weibel–
Palade bodies, which could easily be recognized because of
their characteristic shape (Figure 3, arrowheads; see also
Figure 4). These observations show that endocytosed anti-
bodies against CD63/lamp3 were transported to Weibel–
Palade bodies.
When cells were treated under the same conditions with
nonrelevant antibodies, these did not accumulate intracellu-
larly, presumably because they were transported to lyso-
somes and then degraded (Figure 3). We then investigated
whether antibodies against other antigens present in late
endosomes were also transported to Weibel–Palade bodies.
In these experiments, cells were incubated with our mAb
against LBPA or with a mAb against lgp110/lamp2. As
shown in Figure 3, both antibodies accumulated intracellu-
larly upon binding to their respective antigens, much like
antibodies against CD63/lamp3; however, unlike CD63/
lamp3, antibodies against LBPA or lgp110/lamp2 remained
in late endosomes and were not redistributed to Weibel–
Palade bodies. These experiments thus indicate that anti-
CD63/lamp3 antibodies were selectively transported to
Weibel–Palade bodies while bound to their antigen, and
thus that CD63/lamp3 molecules can traffic from endo-
somes back to Weibel–Palade bodies.
We then followed the movement of internalized, fluores-
cent anti-CD63/lamp3 antibodies after incubating cells for
increasing periods of time (Figure 4, green). After fixation,
cells were labeled with antibodies against LBPA (Figure 4,
red) and vWF (Figure 4, blue) and then inspected by triple-
channel fluorescence. Within 30 min after internalization,
anti-CD63/lamp3 antibodies were detected in vesicles at the
cell periphery, which did not contain LBPA or vWF, and
presumably corresponded to early endosomes. After longer
incubation times, antibody molecules accumulated in late
endosomes containing LBPA, where they remained for sev-
eral hours (4 h incubation shown in Figure 3). Then, no
antibody could be detected within Weibel–Palade bodies
containing vWF. It is only after much longer incubation
times that antibodies against CD63/lamp3 eventually redis-
tributed to Weibel–Palade bodies containing vWF (Figure 4,
after 24 h; see also Figure 5).
Altogether these experiments show that anti-CD63 anti-
bodies appear sequentially in late endosomes and then in
Weibel–Palade bodies and that these two steps are well-
separated in time. Because CD63/lamp3 itself distributes
predominantly to late endosomes, the simplest interpreta-
tion is that CD63/lamp3 molecules tagged with internalized
antibodies, perhaps within late endosomes, are transported
from late endosomes to Weibel–Palade bodies.
Kinetics of P-Selectin and CD63/lamp3 Movement to
Weibel–Palade Bodies
We then compared the transport of CD63/lamp3 to Weibel–
Palade bodies with that of P-selectin, an adhesion molecule
present in Weibel–Palade bodies (Bonfanti et al., 1989;
McEver et al., 1989). Previous studies showed that P-selectin
can cycle from the cell surface to Weibel–Palade bodies
(Subramaniam et al., 1993).
Cells were incubated with antibodies against P-selectin or
CD63/lamp3, as above. After incubation for 1 h, small
amounts of either antibody could already be detected intra-
Figure 3. Antibody-tagged CD63/lamp3 is present in both late en-
dosomes and Weibel–Palade bodies. HUVEC were grown in the pres-
ence of the monoclonal anti-CD63/lamp3, anti-LBPA, anti-lgp110/
lamp 2, or control mouse IgG for 24 h. For optimal detection of
internalized antibodies, these were used at a concentration of 50 mg/ml
in the medium and revealed by indirect immunofluorescence. Cells
were then fixed and stained with FITC-conjugated goat anti-mouse
antibodies. Anti-CD63/lamp3 is internalized into both late endosomes
and Weibel–Palade bodies, which were recognized by their character-
istic rod-shaped structure (arrowheads). Bar, 10 mm.
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cellularly, presumably within endosomes (Figure 5, A and B,
top panels). At that time, no colocalization was observed
with vWF, hence antibodies had not reached Weibel–Palade
bodies; however, after 2 h of incubation, antibody-tagged
P-selectin could already be detected within Weibel–Palade
bodies containing the vWF (Figure 5B). Interestingly, only a
very small subset of Weibel–Palade bodies contained tagged
P-selectin, presumably corresponding to newly formed se-
cretory granules. In marked contrast, antibodies against
CD63/lamp3 remained restricted to late endosomes (Figure
5A), consistent with the time-course shown in Figure 4.
Eventually, after 8 h incubation, CD63/lamp3 molecules
tagged with antibodies started to appear in Weibel–Palade
bodies. Only a subset of these granules, however, was la-
beled at this time, as observed with P-selectin. After 24 h,
most Weibel–Palade bodies contained both antibodies, sug-
Figure 4. Antibody-tagged CD63/lamp3 is transported to late endosomes and then to Weibel–Palade bodies. HUVEC were grown in the
presence of 50 mg/ml Oregon Green-conjugated anti-CD63/lamp3 antibodies. At appropriate time intervals, cells were fixed and triple-
labeled with Alexa 568-conjugated anti-LBPA antibodies and rabbit anti-vWF antibodies followed by AMCA-conjugated donkey F(ab9)2
against rabbit antibodies. Arrowheads show LBPA-positive late endosomes, whereas arrows show vWF-positive Weibel–Palade bodies.
Amounts of internalized antibodies, hence green fluorescence intensity, increased with incubation time. Exposure time was thus adjusted so
that labeled structures could be well resolved. Bar, 10 mm.
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gesting that granule turnover was complete by this time. We
could not detect antibody-tagged CD63 or P-selectin in the
Golgi complex/trans-Golgi network (TGN), presumably be-
cause transport through this compartment is rapid (Figure
5). It is highly unlikely that differences between P-selectin
and CD63/lamp3 reflected differences in antibody endocy-
tosis rates, hence intracellular accumulation. Large amounts
of anti-CD63/lamp3 antibodies accumulated intracellularly,
when compared with P-selectin antibodies, before CD63/
lamp3 movement to Weibel–Palade bodies could be de-
tected. These results thus indicate that the rate of CD63/
lamp3 movement from endosomes to Weibel–Palade bodies
is slow when compared with P-selectin cycling.
CD63/lamp3 and P-Selectin Cycle from Late
Endosomes to Weibel–Palade Bodies
Our time-course experiments suggest that CD63/lamp3 is
transported from late endosomes to Weibel–Palade bodies
and that P-selectin may follow the same route, but far more
efficiently. To investigate this process in more detail, we
used the drug U18666A, which causes selective accumula-
tion of low density lipoprotein-derived cholesterol in late
endocytic compartments and thereby mimics the genetic
disorder Niemann-Pick Type C (Liscum and Klansek, 1998).
Recently, we showed that cholesterol accumulates in late
endosomes containing LBPA of human fibroblasts and baby
hamster kidney cells, and that this accumulation inhibits
cycling of the multifunctional receptor (IGF2/MPR) for in-
sulin-like growth factor 2 and ligands bearing mannose
6-phosphate, in particular lysosomal enzymes (Kobayashi et
al., 1999). The receptor remains trapped in late endosomes,
presumably because cholesterol accumulation interferes
with the membrane physicochemical and dynamic proper-
ties (Kobayashi et al., 1999). Cholesterol accumulation in late
endosomes, however, does not affect TGN38 (Kobayashi et
al., 1998; Kobayashi et al., 1999), which rapidly cycles be-
tween endosomes and TGN (Reaves et al., 1993). Cholesterol
accumulated in late endosomes can easily be detected by
light microscopy using filipin as a fluorescent marker (Sokol
et al., 1988; Kobayashi et al., 1999).
U18666A treatment of HUVEC caused accumulation of
cholesterol within late endosomes containing LBPA, as we
had observed in human fibroblasts and baby hamster kidney
cells (Figure 6). In these experiments, exposure times were
adjusted for the detection of accumulated cholesterol and
were too short to reveal cholesterol present on the plasma
membrane, in early endosomes and in the TGN (Kobayashi
et al., 1999). After cholesterol accumulation in U18666A-
treated cells, antibodies were endocytosed and reached pe-
rinuclear, cholesterol-positive late endosomes; however, an-
tibody-tagged CD63/lamp3 molecules remained trapped in
these endosomes and were no longer transported to Weibel–
Palade bodies, even after 24 h (Figure 6). When U18666A-
treated cells were incubated with control preimmune anti-
bodies, these did not accumulate intracellularly, as in control
cells (Figure 1), presumably because the antibodies were
degraded in lysosomes. These observations thus demon-
strate that cycling of CD63/lamp3 through late endosomes
was inhibited after U18666A-mediated cholesterol accumu-
lation in this compartment, much like IGF2/MPR (Koba-
yashi et al., 1999).
When the experiment was repeated after internalization of
anti-P-selectin antibodies, we found that they were also
endocytosed and then retained within late endosomes. An-
tibody-tagged P-selectin did not reach Weibel–Palade bod-
ies, even after 24 h, although these were normally labeled
within 2 h in the absence of the drug (Figures 5 and 6). These
experiments thus indicate that P-selectin is rapidly trans-
ported through late endosomes (Figure 5), consistent with
the presence of a sorting motif responsible for its transport
from early to late endosomes (Blagoveshchenskaya et al.,
1998a,b) and that cycling is inhibited by cholesterol accumu-
lation.
Finally, cells were incubated with antibodies against CD63
for 2 h and then chased for increasing periods of time to
follow the trafficking of a pulse of antibody-tagged CD63/
lamp3 molecules (Figure 7). Small amounts of antibody were
detected intracellularly after the pulse, presumably within
early endosomes. Then, antibodies accumulated within late
endosomes during the chase, where they remained for sev-
eral hours (in agreement with Figures 4 and 5A). It is only
after long chase time periods that the pulse of antibody-
tagged CD63/lamp3 molecules reached Weibel–Palade bod-
ies. As expected, endosome labeling was then significantly
lower when compared with that observed after continuous
incubation with antibodies for the same time period (Figures
4 and 5A). Also as expected, only fewer Weibel–Palade
bodies were labeled after chase when compared with con-
tinuous incubations. When cells were treated with U18666A
before the experiment, internalized antibodies reached late
endosomes, where they accumulated, but subsequent trans-
port to the Weibel–Palade bodies was inhibited significantly,
in agreement with Figure 6. These experiments demonstrate
that CD63 molecules are transported from late endosomes to
Weibel–Palade bodies.
Similar pulse–chase experiments with antibodies against
P-selectin showed that antibody-tagged P-selectin was de-
tected in endosomes after a 1-h pulse but then rapidly
reached Weibel–Palade bodies (Figure 7B), in agreement
with data shown in Figure 5B. Again, movement of antibod-
ies to Weibel–Palade bodies during the chase was signifi-
cantly reduced in cells treated with U18666A (Figure 7B).
Altogether, these data indicate that both CD63/lamp3 and
P-selectin traffic from late endosomes to Weibel–Palade bod-
ies in human endothelial cells, albeit with very different
kinetics.
DISCUSSION
In the present study, we show that the vast majority of the
tetraspanin CD63/lamp3 in endothelial cells is present
within the complex network of internal membranes rich in
LBPA, which is characteristic for late endosomes; however,
some CD63/lamp3 is also present within specialized secre-
tory granules, the Weibel–Palade bodies, in agreement with
previous studies (Vischer and Wagner, 1993). We find that
CD63/lamp3 molecules can be transported from late endo-
somes to Weibel–Palade bodies and thus that CD63/lamp3
cycles between endocytic and biosynthetic compartments.
Kinetics of this transport, however, are slow when com-
pared with P-selectin, which appears to follow the same
route. These observations are consistent with the notion that
a retention mechanism selective for this tetraspanin exists in
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late endosomes, perhaps corresponding to CD63/lamp3
preferential partitioning within LBPA-rich internal mem-
brane domains within late endosomes; however, our obser-
vations also indicate that the tetraspanin CD63/lamp3 can
eventually recycle from internal membranes of late endo-
somes to be reused in Weibel–Palade body biogenesis.
Figure 5.
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Figure 5 (facing page). Kinetics of antibody-tagged P-selectin and CD63/lamp3 transport to Weibel–Palade bodies. Cells were grown in the
presence of monoclonal antibodies against CD63/lamp3 (A) or P-selectin (B). At appropriate time intervals, cells were fixed and analyzed by
fluorescence microscopy. Anti-CD63/lamp3 antibodies were used at a concentration of 20 mg/ml in the medium, whereas antibodies against
P-selectin conjugated to Alexa 568 were used at a concentration of 5 mg/ml. CD63/lamp3 and vWF were revealed by indirect immunoflu-
orescence. Arrowheads show vWF-positive Weibel–Palade bodies. As in Figure 4, exposure times were adjusted so that labeled structures
could be well resolved. Bar, 10 mm.
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Intracellular Distribution of CD63
The tetraspanin superfamily contains proteins involved in
diverse processes at the cell surface, including proliferation,
adhesion, and motility, and can form complexes with inte-
grins and other cell-surface proteins (Maecker et al., 1997);
however, this superfamily also contains members that were
previously shown to be selectively enriched within internal
membranes of multivesicular endosomes in antigen-present-
ing cells, megakaryocytes, neutrophils, and platelets (Cieu-
tat et al., 1998; Escola et al., 1998; Hammond et al., 1998;
Heijnen et al., 1998).
We now find that $80% of total CD63/lamp3 in HUVEC
localizes to the complex network of LBPA-rich internal
membranes present within multivesicular–multilamellar
late endosomes. CD63/lamp3 carries an 11-residue cytoplas-
mic domain, which encodes a C-terminal lysosomal sorting
motif (Gly-Tyr-X-X-Met) (Hunziker and Geuze, 1996). Al-
though other lysosomal glycoproteins, including lgp120/
lamp1, share this Gly-Tyr motif with CD63/lamp3, lgp120/
lamp1 is restricted to the limiting membranes of late
endosomes (Griffiths et al., 1988; Aniento et al., 1993; Koba-
yashi et al., 1998). Thus, this motif cannot be responsible for
sorting lgp120/lamp1 and CD63/lamp3 into different endo-
somal membrane domains. In addition, this motif cannot
target CD63/lamp3 to Weibel–Palade bodies, because it is
present in lgp120/lamp1 and lgp110/lamp2, which are not
Figure 6. U18666A inhibits transport of antibody-tagged CD63/lamp3 and P-selectin to Weibel–Palade bodies. Top panel: HUVEC were
grown in the absence (control) or presence of 1 mg/ml U18666A for 24 h (U18666A). Cells were then fixed and double-labeled with the
anti-LBPA antibody and filipin. Bottom panel: HUVEC were preincubated with 1 mg/ml U18666A for 24 h followed by an additional 24 h
incubation with the same concentration of U18666A in the presence of anti-CD63 antibody (20 mg/ml) or Alexa 568-labeled anti-P-selectin
(5 mg/ml) antibody. Cells were then fixed and permeabilized; CD63 antibody was revealed with FITC-conjugated goat anti-mouse antibodies,
and all coverslips were double-labeled with antibodies against vWF. Bar, 10 mm.
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found in these granules. Future work will be required to
identify the molecular mechanisms regulating CD63/lamp3
targeting.
Relationships between Secretory Lysosomes and
Weibel–Palade Bodies
In addition to its endosomal localization, we also find that
CD63/lamp3 distributes to Weibel–Palade bodies in
HUVEC, as reported previously (Vischer and Wagner, 1993).
CD63/lamp3 is also present in the secretory lysosomes of
hemopoietic cells (Nieuwenhuis et al., 1987; Griffiths, 1996),
including in both multivesicular bodies and a-granules of
megakaryocytes and platelets (Heijnen et al., 1998) and
azurophilic granules of neutrophils (Cieutat et al., 1998);
however, unlike secretory lysosomes (Wagner, 1993), Wei-
bel–Palade bodies do not contain lysosomal hydrolases. In
fact, the biogenesis of these secretory granules is not well
characterized, and different sorting mechanisms for P-selec-
tin may be used in platelets and endothelial cells (Hartwell
et al., 1998). Although the precise relationships between
Weibel–Palade bodies and secretory lysosomes clearly re-
main to be characterized, the presence of the tetraspanin
CD63/lamp3 in both types of organelles suggests the exis-
tence of some common functional characteristics. This
agrees with the recent identification of a common precursor
for hemopoietic and endothelial cells (Choi et al., 1998).
Cycling of CD63
Antibodies against CD63/lamp3 are internalized by
HUVEC and sequentially appear in early and then late
endosomes. Once in late endosomes, antibody molecules are
specifically retained, upon binding to their antigen, for sev-
eral hours. Then, after .8–10 h, CD63/lamp3 tagged with
antibodies, but not other lysosomal antigens, is selectively
transported from late endosomes to Weibel–Palade bodies.
Our data also indicate that P-selectin follows the same route,
but with much faster kinetics (’2 h).
We found that some, but not all, Weibel–Palade bodies
contained antibody-tagged CD63/lamp3 and P-selectin at
early times in their respective cycle (2 h for P-selectin; 8 h for
CD63/lamp3) or after pulse–chase. In contrast, most Wei-
bel–Palade bodies contained both proteins after long time
periods of continuous antibody internalization (24 h). Incor-
poration of P-selectin and CD63 into Weibel–Palade bodies
reflects basal granule turnover, because cells were not stim-
ulated in our experiments. Incidentally, from the continuous
antibody exposure experiments we can estimate that the
basal granule turnover rate is ;24 h. These observations
suggest that proteins tagged with internalized antibody are
selectively incorporated into newly formed Weibel–Palade
bodies and thus that they are transported from late endo-
somes to the TGN, presumably following the same pathway
as recycling IGF2/MPR molecules (Kornfeld, 1992). Because
we failed to detect tagged antibodies in the TGN, transit
through this organelle may be comparatively rapid. Our
data thus show that in endothelial cells, CD63/lamp3 re-
turns to the storage granules after secretion, like P-selectin
(Subramaniam et al., 1993) but less efficiently, to be reused,
and that this recycling process occurs via late endosomes.
Determinants responsible for P-selectin trafficking and
targeting have been identified. After endocytosis, transport
to late endosomes requires a motif present in the cytoplas-
mic domain (Blagoveshchenskaya et al., 1998a,b), whereas
P-selectin targeting to Weibel–Palade bodies depends on
both the cytoplasmic domain and the transmembrane region
(Koedam et al., 1992; Fleming et al., 1998; Hartwell et al.,
1998). In contrast, the motif(s) responsible for CD63/lamp3s
targeting to Weibel–Palade bodies is not known, and no
sequence homology is observed between P-selectin and
CD63/lamp3 cytoplasmic domains; however, in addition to
this putative sorting signal, we wish to propose that selec-
tive retention of CD63/lamp3 in late endosomes contributes
to the sorting process.
Internal Membranes of Late Endosomes: A Sorting
Mechanism?
Our quantitative studies show that at steady state most
CD63/lamp3 is present within the complex network of
LBPA-rich internal membranes, which accumulates within
late endosomes. Yet, antibody-tagged CD63/lamp3 can cy-
cle from late endosomes and reach Weibel–Palade bodies
(after pulse–chase or continuous internalization of antibod-
ies) and can eventually lead to complete labeling of most
secretory granules after 24 h of continuous antibody inter-
nalization. The simplest interpretation of these observations
is that CD63/lamp3 recycles from late endosome internal
membranes toward the secretory pathway.
The fate of proteins present in internal membranes of mul-
tivesicular–multilamellar compartments has been the subject of
much debate. Because the downregulated epidermal growth
factor receptor accumulates in internal membranes of multive-
sicular endosomes, it was proposed that formation of these
internal membranes represents a mechanism used for the ly-
sosomal degradation of both bilayer and cargo (Futter et al.,
1996). Liposomes containing LBPA (or other anionic lipids)
were also shown to enhance glucosylceramide degradation in
vitro (Wilkening et al., 1998). If LBPA-rich membranes can
incorporate molecules destined to be degraded, it is unlikely,
however, that the bilayer itself becomes degraded, because
LBPA is both poorly degradable, because of its unique stereo-
configuration (Brotherus et al., 1974), and very abundant within
internal membranes (Kobayashi et al., 1998).
Internal membranes of late endosomes also appear to
contain proteins that are destined to be reused. It has been
proposed that IGF2/MPR cycles between internal mem-
branes of late endosome (prelysosome) and the TGN (Grif-
fiths et al., 1988). Consistent with this view, we found that
IGF2/MPR accumulates within LBPA-rich internal mem-
branes of late endosomes when cycling is inhibited (Koba-
yashi et al., 1998). In antigen-presenting cells, a specialized
pathway allows the direct fusion of multivesicular compart-
ments with the plasma membrane, releasing into the me-
dium internal membranes (exosomes) enriched in some tet-
raspanins (Escola et al., 1998; Geuze, 1998). As at other
transport steps, future studies will be required to determine
the precise mechanisms that regulate within these internal
membranes the sorting/trafficking of proteins destined to be
recycled or degraded; however, some insights can already
be gained from this and other studies. Our previous work
suggested that LBPA-rich internal membranes function as
distribution device for low density lipoprotein-derived cho-
lesterol and contribute to IGF2/MPR sorting/trafficking
(Kobayashi et al., 1998,1999). It is attractive to propose that
CD63/lamp3 Cycling
Vol. 11, May 2000 1839
endosome internal and limiting membranes interact in a
highly dynamic manner, perhaps via intraluminal fusion/
fission events. These dynamic properties may contribute
to regulate protein movement, including CD63/lamp3,
through the compartment, in combination with yet to be
discovered regulatory mechanisms.
Figure 7.
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Figure 7 (facing page). Pulse–chase analysis of endosome to Weibel–Palade bodies transport. Cells were incubated in the presence of mAbs
against CD63/lamp3 for 2 h (A) or P-selectin for 1 h (B) (pulse) and then further incubated in the absence of antibody for the indicated time
period (chase). Anti-CD63/lamp3 antibodies were used at a concentration of 20 mg/ml in the medium and revealed by indirect immuno-
fluorescence, whereas antibodies against P-selectin were directly conjugated with Alexa 568 and used at a concentration of 5 mg/ml. Cells
were fixed and analyzed by double-immunofluorescence microscopy using antibodies against vWF. As in Figure 4, exposure times were
adjusted so that labeled structures could be well resolved. Bar, 10 mm.
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The movement of CD63/lamp3 from late endosomes to
Weibel–Palade bodies is slow when compared with that of
P-selectin, and unlike P-selectin, CD63/lamp3 accumulates
in late endosomes. Preferential partitioning of CD63/lamp3
within LBPA-rich membrane domains in late endosomes
may thus contribute to an increased CD63/lamp3 residence
time in this compartment, hence leading to its accumulation.
This mechanism may decrease the number of molecules
accessible to transport intermediates forming on the cyto-
plasmic face of late endosome limiting membrane and thus
reduce CD63/lamp3 trafficking rates. In contrast, the cycle
of P-selectin is much faster than that of CD63/lamp3, and
P-selectin does not accumulate in late endosomes of endo-
thelial cells. P-selectin may have a somewhat reduced ten-
dency to partition within LBPA-rich membranes and thus
may be more readily transported. We could not determine
the distribution of P-selectin on internal versus limiting
membranes of late endosomes in endothelial cells, because
amounts of the protein are too low to be detected at steady
state; however, this analysis was possible in megakaryocytes
and showed that P-selectin is present on both internal and
limiting membranes of multivesicular bodies and a-gran-
ules, in contrast to CD63, which was enriched on internal
membranes (Heijnen et al., 1998). Thus, we propose that the
LBPA-rich membrane domain functions as a retention mech-
anism for CD63/lamp3, as well as perhaps for other mole-
cules, including presumably other tetraspanins, which are
enriched within late endosome internal membranes.
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